

House \_\_\_\_\_ Amendment NO. \_\_\_\_\_

Offered By \_\_\_\_\_

1 AMEND House Committee Substitute for House Bill No. 2372, Page 8, Section 190.246, Line  
2 41, by inserting after all of said section and line the following:

3  
4 "191.647. 1. As used in this section, the following terms mean:

5 (1) "DEHP", di(2-ethylhexyl) phthalate;

6 (2) "Intentionally added DEHP", DEHP that a manufacturer has intentionally added to a  
7 product and that has a functional or technical effect on the product;

8 (3) "Intravenous solution container", a container used to house medicine, fluid, or  
9 nutrition therapy that is intravenously delivered to a patient in a hospital, outpatient facility, or  
10 other health care facility;

11 (4) "Intravenous tubing", tubing used to intravenously administer fluids, medication, or  
12 nutrients directly to an adult, child, or infant;

13 (5) "Ortho-phthalate", a class of chemicals that are esters of ortho-phthalic acid,  
14 including DEHP or any of the following:

15 (a) Benzyl butyl phthalate (BBP);

16 (b) Dibutyl phthalate (DBP);

17 (c) Dicyclohexyl phthalate (DCHP);

18 (d) Diethyl phthalate (DEP);

19 (e) Diisobutyl phthalate (DIBP);

20 (f) Diisodecyl phthalate (DIDP);

21 (g) Diisononyl phthalate (DINP);

22 (h) Di-n-hexyl phthalate (DnHP);

23 (i) Di-n-octyl phthalate (DNOP);

24 (j) Di-n-pentyl phthalate (DnPP); or

25 (k) Diisoheptyl phthalate (DIHP);

26 (6) "Unintentionally added DEHP", DEHP in an intravenous solution container or  
27 intravenous tubing product that is not used for functional or technical effect on the product.

28 2. Beginning January 1, 2030, a person or entity shall not sell or distribute into  
29 commerce in this state intravenous solution containers made with intentionally added DEHP.

Action Taken \_\_\_\_\_ Date \_\_\_\_\_

1           3. Beginning January 1, 2035, a person or entity shall not manufacture, sell, or distribute  
2 into commerce in this state intravenous tubing made with intentionally added DEHP.

3           4. A person or entity subject to the prohibitions in this section shall not replace DEHP  
4 with another ortho-phthalate in a new or revised medical device.

5           5. An intravenous solution container or intravenous tubing product shall not have  
6 unintentionally added DEHP present at a quantity at or above one-tenth of one percent weight  
7 per weight.

8           6. The following items, as described in Title 21 of the Code of Federal Regulations, shall  
9 be exempt from the requirements of this section:

10           (1) Human blood collection and storage bags; and

11           (2) Apheresis and cell therapy blood kits and bags, including integral tubing.

12           7. The date of January 1, 2030, by which compliance is required for a person or entity  
13 under subsection 2 of this section shall be extended to January 1, 2032, if all of the following  
14 conditions are met:

15           (1) The need for an extension is due to pending United States Food and Drug  
16 Administration approval for the DEHP-free intravenous solution container or due to the  
17 manufacturer not having adequate equipment to manufacture the DEHP-free intravenous  
18 solution container;

19           (2) The person or entity notified its Missouri customers, before October 1, 2026, that it  
20 has commenced development of the DEHP-free intravenous solution container to meet the  
21 requirements of this section; and

22           (3) The person or entity provides notice to its customers and posts to its official internet  
23 website, before January 1, 2028, that it will not meet the deadline imposed under subsection 2 of  
24 this section."; and

25  
26 Further amend said bill by amending the title, enacting clause, and intersectional references  
27 accordingly.